# GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

> **NCT02799147** · PHASE1,PHASE2 · COMPLETED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 27 (actual)

## Conditions studied

- Leukemia, Acute Lymphoblastic
- Acute Myeloid Leukemia
- Mixed-Lineage Acute Leukemias

## Interventions

- **PROCEDURE:** Allogeneic stem cell transplantation
- **DRUG:** Fludarabine monophosphate
- **DRUG:** Busulfan
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT02799147
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-11
- **Final completion:** 2020-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02799147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02799147, "GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02799147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*